- Home
- GENK vs QTTB Comparison
GENK vs QTTB Comparison
Compare GENK & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- QTTB
- Stock Information
- Founded
- GENK 2011
- QTTB 2015
- Country
- GENK United States
- QTTB United States
- Employees
- GENK N/A
- QTTB N/A
- Industry
- GENK Restaurants
- QTTB Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- QTTB Health Care
- Exchange
- GENK Nasdaq
- QTTB Nasdaq
- Market Cap
- GENK 20.4M
- QTTB 23.3M
- IPO Year
- GENK 2023
- QTTB N/A
- Fundamental
- Price
- GENK $3.14
- QTTB $1.65
- Analyst Decision
- GENK Strong Buy
- QTTB Hold
- Analyst Count
- GENK 2
- QTTB 8
- Target Price
- GENK $7.00
- QTTB $24.00
- AVG Volume (30 Days)
- GENK 73.2K
- QTTB 113.0K
- Earning Date
- GENK 08-06-2025
- QTTB 08-06-2025
- Dividend Yield
- GENK 3.81%
- QTTB N/A
- EPS Growth
- GENK N/A
- QTTB N/A
- EPS
- GENK N/A
- QTTB N/A
- Revenue
- GENK $216,137,000.00
- QTTB N/A
- Revenue This Year
- GENK $12.35
- QTTB N/A
- Revenue Next Year
- GENK $14.62
- QTTB N/A
- P/E Ratio
- GENK N/A
- QTTB N/A
- Revenue Growth
- GENK 10.67
- QTTB N/A
- 52 Week Low
- GENK $3.13
- QTTB $1.35
- 52 Week High
- GENK $10.33
- QTTB $53.79
- Technical
- Relative Strength Index (RSI)
- GENK 37.18
- QTTB 42.05
- Support Level
- GENK $3.13
- QTTB $1.65
- Resistance Level
- GENK $3.39
- QTTB $1.82
- Average True Range (ATR)
- GENK 0.14
- QTTB 0.16
- MACD
- GENK 0.00
- QTTB -0.02
- Stochastic Oscillator
- GENK 10.58
- QTTB 2.42
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.